A retrospective analysis of breast cancer patients at The University of Kansas Health System found no significant difference in neutropenia-related events (NREs) when pegfilgrastim was administered on the same day an individual received chemotherapy versus the next day.
For the study, researchers conducted a matched-cohort chart review of breast cancer patients who completed at least one cycle of curative-intent chemotherapy and received pegfilgrastim between Jan. 1, 2019, and